Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05552976 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

A Phase 3 study of Relapsed or Refractory Multiple Myeloma, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 3
Development phase
525
Enrollment target
20
Study locations

NCT05552976 is a Phase 3 study of Relapsed or Refractory Multiple Myeloma that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 525 participants, above the 290-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (81% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05552976, a Phase 3 study of Relapsed or Refractory Multiple Myeloma, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
525 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

Conditions Studied

Relapsed or Refractory Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Carfilzomib
  • DRUG Mezigdomide

Study Locations (20)

California

  • Local Institution - 0005 - Cerritos
  • Local Institution - 0190 - Irvine
  • Local Institution - 0187 - Los Angeles
  • Local Institution - 0344 - Santa Rosa
  • Local Institution - 0339 - Stockton

Florida

  • Local Institution - 0341 - Fort Myers
  • Local Institution - 0342 - St. Petersburg
  • Local Institution - 0340 - West Palm Beach

Georgia

  • Local Institution - 0348 - Atlanta
  • Local Institution - 0291 - Atlanta

Ohio

  • Local Institution - 0322 - Cleveland
  • Local Institution - 0172 - Columbus

Alabama

  • Local Institution - 0046 - Mobile

Delaware

  • Local Institution - 0279 - Newark

Idaho

  • Saint Alphonsus Regional Medical Center - Boise

Maryland

  • Local Institution - 0289 - Annapolis

Trial Details

FieldValue
Enrollment Target 525 participants
Start Date 2023-01-10
Est. Completion 2029-07-25
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05552976

The ClinicalTrials.gov registry entry for NCT05552976 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 525 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 290-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (81% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.

NCT05552976 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT05552976 about?

NCT05552976 is a clinical study titled "A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)". The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

What is the current status of trial NCT05552976?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 525 participants. The study started on 2023-01-10. Estimated completion is 2029-07-25.

What conditions does trial NCT05552976 study?

This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.

What interventions are being tested in trial NCT05552976?

The interventions under investigation include: Dexamethasone (DRUG), Carfilzomib (DRUG), Mezigdomide (DRUG).

Who is sponsoring clinical trial NCT05552976?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05552976 being conducted?

This trial has 20 study locations across Alabama, California, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsed or Refractory Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Relapsed or Refractory Multiple Myeloma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.